BioMarin Pharmaceutical Inc. (BMRN) Shares Sold by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio cut its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 6.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 76,175 shares of the biotechnology company’s stock after selling 4,823 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in BioMarin Pharmaceutical were worth $6,486,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Commonwealth Bank of Australia increased its position in shares of BioMarin Pharmaceutical by 49.6% during the fourth quarter. Commonwealth Bank of Australia now owns 350 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 116 shares during the period. Nordea Investment Management AB increased its position in shares of BioMarin Pharmaceutical by 2.1% during the third quarter. Nordea Investment Management AB now owns 7,206 shares of the biotechnology company’s stock valued at $699,000 after purchasing an additional 147 shares during the period. State of Alaska Department of Revenue increased its position in shares of BioMarin Pharmaceutical by 0.8% during the fourth quarter. State of Alaska Department of Revenue now owns 21,807 shares of the biotechnology company’s stock valued at $1,856,000 after purchasing an additional 175 shares during the period. Sumitomo Mitsui Asset Management Company LTD increased its position in shares of BioMarin Pharmaceutical by 1.9% during the fourth quarter. Sumitomo Mitsui Asset Management Company LTD now owns 10,783 shares of the biotechnology company’s stock valued at $918,000 after purchasing an additional 205 shares during the period. Finally, Tocqueville Asset Management L.P. increased its position in shares of BioMarin Pharmaceutical by 0.3% during the fourth quarter. Tocqueville Asset Management L.P. now owns 85,689 shares of the biotechnology company’s stock valued at $7,296,000 after purchasing an additional 219 shares during the period.

In other BioMarin Pharmaceutical news, CEO Jean Jacques Bienaime sold 4,000 shares of the stock in a transaction dated Tuesday, February 5th. The stock was sold at an average price of $98.63, for a total value of $394,520.00. Following the transaction, the chief executive officer now owns 292,290 shares of the company’s stock, valued at $28,828,562.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director V Bryan Lawlis sold 2,150 shares of the stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $89.76, for a total value of $192,984.00. Following the completion of the transaction, the director now directly owns 21,310 shares in the company, valued at approximately $1,912,785.60. The disclosure for this sale can be found here. Insiders sold 80,585 shares of company stock worth $7,399,339 in the last three months. Insiders own 1.90% of the company’s stock.

A number of analysts have recently issued reports on BMRN shares. Oppenheimer assumed coverage on BioMarin Pharmaceutical in a research report on Thursday, December 13th. They set a “hold” rating and a $92.00 price objective on the stock. Wolfe Research assumed coverage on BioMarin Pharmaceutical in a research note on Friday, December 14th. They issued an “outperform” rating on the stock. Guggenheim assumed coverage on BioMarin Pharmaceutical in a research note on Monday, December 17th. They issued a “neutral” rating on the stock. Zacks Investment Research lowered BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Monday, December 31st. Finally, Raymond James lowered BioMarin Pharmaceutical from an “outperform” rating to a “market perform” rating and set a $83.16 price objective on the stock. in a research note on Wednesday, January 2nd. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have given a buy rating to the company’s stock. BioMarin Pharmaceutical has an average rating of “Buy” and a consensus target price of $112.82.

Shares of BMRN opened at $89.43 on Tuesday. The company has a current ratio of 3.93, a quick ratio of 2.92 and a debt-to-equity ratio of 0.28. BioMarin Pharmaceutical Inc. has a 12-month low of $75.81 and a 12-month high of $106.74. The firm has a market cap of $15.95 billion, a PE ratio of -271.00 and a beta of 1.52.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings results on Thursday, February 21st. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.07. BioMarin Pharmaceutical had a negative return on equity of 2.79% and a negative net margin of 5.18%. The business had revenue of $353.00 million for the quarter, compared to analyst estimates of $377.35 million. During the same quarter in the prior year, the firm posted $0.03 earnings per share. The firm’s revenue for the quarter was down 1.4% compared to the same quarter last year. Research analysts anticipate that BioMarin Pharmaceutical Inc. will post 0.02 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “BioMarin Pharmaceutical Inc. (BMRN) Shares Sold by Public Employees Retirement System of Ohio” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://sportsperspectives.com/2019/04/02/biomarin-pharmaceutical-inc-bmrn-shares-sold-by-public-employees-retirement-system-of-ohio.html.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Further Reading: Determine Your Level of Risk Tolerance

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.